Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant ...

The mechanism we delineated … can be targeted at multiple levels with existing drugs, potentially improving disease outcomes in this patient population,” said Lorenzo Galluzzi, PhD.

Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

The FDA has accepted for review the NDA for vepdegestrant to treat ESR1-mutated, ER+, HER2- advanced breast cancer.

A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT ...

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ...

It’s a very different world now in cancer,” said longtime patient advocate Ginny Mason. “Now you need to understand the ...

DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Operator: Good morning, and welcome to Mersana Therapeutics Second Quarter 2025 Financial Results and Business Update ...

A "pea-sized lump" she noticed on her breast turned out to be stage 1 breast cancer. The post Woman gets breast cancer ...